ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 0986

Ianalumab (VAY736) Safety and Efficacy in Patients with Sjögren’s Syndrome: 52 Week Results from a Randomized, Placebo-controlled, Phase 2b Dose-ranging Trial

Thomas Dörner1, Simon J Bowman2, Robert Fox3, Xavier Mariette4, Athena Papas5, Thomas Grader-Beck6, Ben A Fisher2, Filipe Barcelos7, Salvatore De Vita8, Hendrik Schulze-Koops9, Robert Moots10, Guido Junge11, Janice Woznicki12, Monika Sopala11, Wen-Lin Luo12 and Wolfgang Hueber11, 1Charite Universitätsmedizin Berlin and Deutsches Rheumaforschungszentrum (DRFZ), Berlin, Germany, 2Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, 3Scripps Memorial Hospital and Research Institute, San Diego, CA, 4Université Paris- Saclay, Rheumatology, Paris, France, 5Division of Oral Medicine, Tufts School of Dental Medicine, Boston, MA, 6Johns Hopkins University, Baltimore, MD, 7Instituto Português de Reumatologia, Lisbon, Portugal, 8Division of Rheumatology, DAME, University Hospital of Udine, Udine, Italy, 9Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany, 10Academic Rheumatology Department, Aintree University Hospital, Liverpool, United Kingdom, 11Novartis Pharma AG, Basel, Switzerland, 12Novartis Pharmaceuticals Corporation, East Hanover, NJ

Meeting: ACR Convergence 2021

Keywords: , , , ,

Session Information

Date: Sunday, November 7, 2021

Title: Abstracts: Sjögren's Syndrome – Basic & Clinical Science (0984–0987)

Session Type: Abstract Session

Session Time: 4:00PM-4:15PM

Background/Purpose: Sjögren’s syndrome (SS) is an autoimmune disease affecting excretory glands and characterized by B-cell hyperactivity. Ianalumab (VAY736) is a human monoclonal antibody to B-cell activating factor receptor, engineered for direct ADCC-mediated B-cell depletion. A Phase 2b study evaluated the dose-response of VAY736 vs placebo (PBO) in EULAR SS Disease Activity Index (ESSDAI) change from baseline (CHB) and other secondary endpoints. Primary results at Week (Wk) 24 were reported previously1. Here we report 52 Wks safety and efficacy from extended blinded treatment period 2 (TP2).

Methods: 190 patients were randomized equally to receive s.c. doses of VAY736 (5, 50, 300 mg) or PBO every 4 Wks (q4w). Eligible patients fulfilled American European Consensus Group (AECG) criteria, were anti-Ro/SSA+, had ESSDAI ≥6 and EULAR SS Patient Reported Index (ESSPRI) ≥5. At Wk 24, after completion of the first blinded TP (TP1), PBO-treated patients were switched to VAY736 150 mg, and patients on 300 mg were re-randomized to continue 300 mg or PBO for 28 Wks in TP2. Patients were followed post-treatment for ≥20 Wks. Safety was assessed for all periods. Due to lack of PBO-control in TP2, descriptive efficacy analysis was performed for ESSDAI, ESSPRI, Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F), Physician’s (PhGA) and Patient’s Global Assessments (PaGA), 36-Item Short Form Survey (SF-36), and SS symptom diary (SSSD).

Results: Overall, there was no dose dependency of treatment emergent adverse events (TEAEs) except for injection site reactions, which were mostly mild to moderate in severity. Lymphopenia and neutropenia were mostly grade (G)1 and G2, and none G4. Most common TEAEs were infections and infestations in exposure-adjusted analysis of incidence rates. Nasopharyngitis and upper respiratory tract infections were the most common TEAEs, with no dose response (Table). Tracheobronchitis and pneumonia, were mild to moderate severity, not associated with absolute neutrophil count G3, and none led to treatment withdrawal.
At Wk 52, efficacy was sustained for patients who continued 300 mg in TP2 (ESSDAI, ESSPRI, PaGA, PhGA CHB: –9.06, –1.91, –22.03, and –35.80, respectively). Efficacy was partially lost for patients who switched to PBO at Wk 24 (Figure). Improvement was noted for PBO patients who switched to 150 mg. Stimulated whole salivary flow at Wk 24 was improved for 300 mg (PBO-adjusted CHB 0.20 ml/min; P=0·037); last measurement at Wk 48 was 0.45 and 0.22 ml/min CHB in patients who continued 300 mg or PBO in TP2, respectively.

Conclusion: Ianalumab 300 mg was well tolerated up to 52 Wks. Exploratory efficacy measures showed that continuous dosing of 300 mg s.c. q4w provided sustained clinical benefit. PaGA was the outcome that showed the most prominent change following switch to PBO or VAY736.

Reference:

  1. Dörner T, et al. [OP0302]. Ann Rheum Dis. 2020;79(suppl 1):187.

Table: Key Safety Data (All Study Periods up to Week 52) †

Figure: Summary of Efficacy data at Week 52 (Treatment Period from Wk 24 to Wk 52)

Disclosures: T. Dörner, Eli Lilly, 2, Novartis, 2, Janssen, 2, GSK, 2, Sanofi, 2, Deutsche Forschungsgemeinschaft, 5, AbbVie, 2, Roche, 2, Boston Pharmaceuticals, 2; S. Bowman, Novartis, 1, 2, Astrazeneca, 2, Biogen, 2, BMS, 2, Celgene, 2, Medimmune, 2, MTPharma, 2, Ono, 2, UCB, 2, xtlbio, 2; R. Fox, Novartis, 2, Pfizer, 2, Eli lilly, 2; X. Mariette, GlaxoSmithKline, 2, BMS, 2, Servier, 2, Janssen, 2, Novartis, 2, Pfizer, 2, UCB, 2; A. Papas, Novartis, 2, 5; T. Grader-Beck, Novartis, 2, Abbvie, 5, Eli Lilly, 2, Celgene, 5; B. A Fisher, Novartis, 2, Roche, 2, BMS, 2, Galapagos, 2, Janssen, 2, Servier, 2; F. Barcelos, Pfizer, 2, Eli lilly, 2; S. De Vita, Roche, 2, Human Genome Science, 2, GSK, 2, Novartis, 2; H. Schulze-Koops, Roche/Chugai, 2, 5, 6, Sobi, 6, Novartis, 2, 5, 6, AbbVie, 2, 5, 6, Amgen, 2, 6, Bristol-Myers Squibb, 2, 6, Celgene, 2, 6, Celltrion, 2, 6, Chugai, 2, 6, Gilead Sciences, 2, 6, Janssen, 2, 6, Eli Lilly, 2, 6, MSD, 2, 6, Pfizer Inc, 2, 6, Sanofi, 2, 6, Galapagos, 1, 2, UCB, 1, 2; R. Moots, Amgen, 2, 5, Chugai, 2, 5, Gilead, 2, 5, Eli lilly, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, Roche, 2, 5; G. Junge, Novartis, 3, 11; J. Woznicki, Novartis, 3, 11; M. Sopala, Novartis, 3, 11; W. Luo, Novartis, 3, 11; W. Hueber, Novartis, 3, 11.

To cite this abstract in AMA style:

Dörner T, Bowman S, Fox R, Mariette X, Papas A, Grader-Beck T, A Fisher B, Barcelos F, De Vita S, Schulze-Koops H, Moots R, Junge G, Woznicki J, Sopala M, Luo W, Hueber W. Ianalumab (VAY736) Safety and Efficacy in Patients with Sjögren’s Syndrome: 52 Week Results from a Randomized, Placebo-controlled, Phase 2b Dose-ranging Trial [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/ianalumab-vay736-safety-and-efficacy-in-patients-with-sjogrens-syndrome-52-week-results-from-a-randomized-placebo-controlled-phase-2b-dose-ranging-trial/. Accessed .

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/ianalumab-vay736-safety-and-efficacy-in-patients-with-sjogrens-syndrome-52-week-results-from-a-randomized-placebo-controlled-phase-2b-dose-ranging-trial/